Biology Overseas Development Analysis Technology – Switzerland

Author:ANROSOFT_market survey report Company,market survey report services.( http://anrosoft.com )

Summary of Switzerland in the life sciences, physics, chemistry and other scientific research in a leading position in the field. In the life sciences and biotechnology, the Swiss researchers have high-quality and stable socio-economic environment, preferential tax policies, investment and financing system of sophisticated and unique geographical location and other advantages and research are closely integrated development of the Swiss biotechnology industry Key characteristics. The Government of Switzerland to create a focus on the development of biological science and technology, society, industry and trade environment, will focus on Switzerland to create an international biotechnology company operations and the creation of the first choice.

Switzerland in the life sciences, physics, chemistry behind scientific and technological strength of the United States, are world-class scientific research center, the number of patents per capita (2005EPO), the per capita number of scientific papers published scientific papers, as well as the average impact factor ranks first in the world spaces. Switzerland in the pharmaceutical, chemicals, precision instruments, medical equipment applications, such as among the international forefront of research and development, in the 20th century the natural sciences have had a field of 19 Nobel Prize winners. In the life sciences and biotechnology research areas, Switzerland has a unique advantage, and continuous innovation to maintain a good ability to focus on the Swiss government to create a suitable bio-industrial development in the academic, social, industrial and commercial environment, to save on Switzerland as an international creation and biotechnology company operating the first choice. Study: Chinese influenza vaccine industry market research report

The development of one industry

1  1 scale industries

Switzerland is located in the heart of Europe, with Germany, France and Italy border, forming a bio-technology and industrial development of regional innovation. Ernst & Young data show that Switzerland has the world’s highest per capita number of biotechnology companies. A total of 2006 Swiss biotechnology industry 229 companies, of which more than half of the previous set up in 1997, including 138 engaged in the development of bio-technology companies, 91 biotech suppliers and nine listed companies. Switzerland, a number of core biotechnology companies in Europe the first six, the world’s first 10. Biotechnology in the development of 138 companies, 86% of people active in the field of animal health, 8% were engaged in the field of environmental and industrial research, 6% were engaged in agricultural biotechnology and nutrition research. Around 50% of pharmaceutical companies active in the treatment of health areas, 20% of the genomics and proteomics to carry out technical studies. Switzerland, in 2005 the biotechnology industry of 60 billion Swiss francs in sales, employing approximately 14,400; in 2006 its sales increased by 7.8%, amounting to 6.4 billion Swiss francs, net income reached 917 million Swiss francs.

1  2 regional pattern of industry

Switzerland has 26 cantons, one of 20 states have biotech companies, but mainly concentrated in the Geneva – Lausanne (BioAlps), Basel (BioValleyBasel), Zurich (ZuerichMedNet) and Ticino (BioPoloTicino four gathered biotechnology industry District. BioAlps biology are the most famous European Technology Park, the park has BioArk, Biopole, Neode industries, such as incubators 5, 200 biotechnology companies, including Serono, Medtronic, OMPharma and other world-class pharmaceutical and biotechnology companies, in addition to a collection of well-known universities and research institutes, so that Geneva has become the European leader in biotechnology research place. Basel, Switzerland, Science and Technology Park is located in the north-west, linking the United Kingdom, Germany and Switzerland, the transport hub of the international famous bio-technology base. the global top 10 biopharmaceutical companies Novartis, Roche and a lot of well-known companies both at the headquarters here. In the past 10 years, more than 100 biotechnology companies was born in Basel, to engage in bio-informatics, antibodies, such as nano-machines research. Zurich is the European Technology Park Research Center of Biotechnology, has more than 400 biotechnology and pharmaceutical companies, the world’s leading institutions of higher learning and research institutions and a sound financial system, to attract a large number of venture capital and seed money to the center brings together, in order to the development of biotechnology companies created favorable conditions. Ticino biotechnology park located in southern Switzerland, by providing one-stop services, such as measures to promote and attract biotechnology venture enterprises. related research: The Chinese influenza vaccine industry market research report

1  3 strengths of industrial development

Switzerland has a lot of the development of the advantages of the biotechnology industry has attracted many well-known international biotechnology and chemical companies, has laid a good foundation of industrial development.

First, have a large number of high-quality researchers. Swiss biotechnology – industry gathering area has many excellent universities (including the world’s top universities) and research institutions, bringing together a large number of high-quality researchers, there are only 15,000 at the Basel scientists engaged in life science research, one of 5000 were professor, doctor. A good academic environment to attract global talents to the work of this study, not only for Switzerland, the biological sciences to provide a stable development of personnel, as well as the Swiss scientific and technological innovation continue to provide fresh blood.

Social and political stability are the two economic environment. Swiss social and political stability, the Government has provided in favor of biotechnology development administration and management of the environment, improvement of infrastructure and flexible platform for the market. In Switzerland, the new company can be 2-3 days at the formal establishment and operation, short cycle and Product Registration, innovative drugs, biological products and medical equipment to enter the market easily.

Are three preferential tax policy. Swiss biotechnology industry also benefited from the Government’s incentive policies, such as low-wage tax. Switzerland, in 2003 the average corporate tax rate is 25.5 percent profit margin in 2005 was 21%, the lowest tax rates in Europe.

Are four strategic location. Switzerland is located in central Europe, is the world’s business activities. Departure from Switzerland at 2 hours to reach the European continent in all major cities. Unique position not only in Switzerland and form a multi-cultural, multi-lingual integration of the international exchange of the atmosphere, will also be Switzerland and throughout Europe and the world to link. Geographically close contact has also created conditions to facilitate business, products and services in Switzerland may be subject to any restrictions on entering the European market, Switzerland in the company can enjoy the preferential policies the European Union and Switzerland bilateral. Unique combination of these facilities, so that the Swiss biotechnology industry has become an ideal place to develop.

Friday is the world’s top pharmaceutical, biological, chemical industry, gathered to form a huge network of research and industry. Switzerland, a good environment to attract the industry’s top companies are the world headquarters to this transfer, including Lonza, Novaritis, Roche, Syngenta, Ciza, Clariant, such as transnational corporations, in addition to the traditional Swiss pharmaceutical, fine chemical and manufacturing industries, in Switzerland the formation of a large network of industry, construction of an attractive platform for scientific research and innovation.

2 Government efforts to make the Swiss biotechnology company into an international carrier of choice to create and place

In 2006 by the World Economic Forum in Switzerland as the world’s most competitive countries in the world. Switzerland is Europe’s biotechnology industry in countries with higher maturity. Swiss biotechnology industry’s long-term benefit from the rapid development of the first strong support for the Government. The Government of Switzerland from the management and administration focus on creating an attractive business environment to support the sustainable development of biotechnology industries. At present, Switzerland has four sophisticated gathering of industry groups, a variety of measures to improve the transfer of technology, the world’s top companies gathered in the industrial environment and a variety of private and public capital market.

2  1 sound set up to support the industrial development of the management system

Swiss-funded biotechnology research and basic research targeted mainly government departments are the National Science Foundation (SNSF). SNSF assessment with strict international standards for funding each year more than 7,000 universities and research institutions of researchers, one of 35 researchers under the age of 70%. SNSF-funded in 2006 to CHF 500 million, about 40% of direct funding of biotechnology projects funded or indirectly related to life sciences, physics and chemistry projects and so on. At the SNSF funding have emerged in Cytos, Prionics and Glycart biology and other emerging technology companies. SNSF-funded each year more than 2,000 doctoral students from abroad, attracted a large number of young creative talents.

Federal Technology and Innovation Committee (CTI) is a government-funded biotechnology research, development and application of the main department. In the field of biotechnology, CTI Its main tasks are twofold: First, in support of biotechnology research and application-oriented basic research, the promotion of technological innovation and product development. Are two advantages of technology to improve and create procedures for the development and transformation of the new biotechnology companies have set up to provide targeted support and efficient services for the promotion of Switzerland, the rapid development of biotechnology industries. To this end, the increase in genomics and post-genomics research in the field, such as essential inputs (such as functional analysis, genomics, bioinformatics, proteomics, metabolomics, etc.) input to further enhance the capacity of the Swiss life sciences innovation ; strengthening the emerging field of transformation of the outcome of applications to support and promote sustainable development of biotechnology. CTI Life Sciences at the annual input of about 60 million Swiss francs, of which 40% by the federal government to bear the remaining burden from commercial partners. In addition, CTI year 1000 for salaries researchers. Study: Chinese influenza vaccine industry market research report

CTI funding between 2004-2007 a total of nearly 4 million Swiss francs, funded by the CTI launched nearly a year to attract one million Swiss francs investment risk.

2  2, the implementation of a number of science and technology strategic plan

1992-2001 Switzerland to start “giving priority to the development of biotechnology” plan (SPP), the project investments of CHF 57.8 million between universities and enterprises to promote technology transfer, a total of 251 cooperation projects to support the establishment of 18 new biotechnology companies. 2001-2003 Swiss National Competition Education Center (NCCR) to launch a new funding scheme to provide 43.5 million Swiss francs funded 14 projects, one of seven projects for life science research. Essential for the consolidation of the Swiss at the strategic position of the field, set up and perfect the system for future research, SNSF start “the capacity of the National Research Center (NCCRs) plan,” has been in neuroscience, genetics, structural biology, cancer research and the field of medical technology has set up 20 centers. CTI was launched in 1996, “the risk of laboratory program,” funded a total of 1500 projects, the birth of 140 companies in 2007 to 85 percent of the company is still in normal operation, one-third from one of the life sciences, and 250 set up cooperative relations between the companies. In addition, the Swiss Government’s support for international collaborative research, the department introduced the international research institutions of international scientific and technological plans, such as the European Union research and technological development framework plan, such as Human Frontier Science Program.

2  3 promulgated to amend the relevant laws and regulations and create a favorable policy environment for industrial development

Switzerland enacted in 2000 “with the treatment of clinical research products and medical devices regulations” promulgated in 2003, “Stem Cell Research Bill,” enacted in 2004, “the medical and genetic tests Transplant Ordinance norms,” norms from different angles the area of biotechnology research. Biology in 2005 the Technical Committee to amend the Federal “Patent Law” (draft), take the protection of gene sequences, additional measures such as restrictive clauses, the protection of high input, high-risk biotechnology patents, and enhance the competitiveness of enterprises. In addition, Switzerland has developed a lot of areas in line with the EU legal provisions, at the same time it has a flexible labor laws, the lowest corporate tax rates in Europe, as well as lower payroll taxes. Federal and state governments are making an effort for companies and individuals to provide timely and effective services to create conditions conducive to a favorable environment for industrial development.

2  4 set up a biotechnology industry association and a co-ordinating body

Switzerland in 1998 set up the Technology Association of Biology (ASBC), now has more than 100 member enterprises. Benefits on behalf of the members of the ASBC, with the relevant authorities to improve facilities, promote inter-university members and the transfer of technology, the promotion of biotechnology in Europe and other organizations and contact with the global integration of industrial chain biology. Switzerland, in 2000 the establishment of the Federal focal point for biotechnology, as the field of biotechnology regulations issued license applications, social organizations to carry out activities related to the coordination and management institutions and biotechnology companies to provide the necessary information relevant laws and regulations. Switzerland has also set up a basic database of biotechnology in Switzerland, the Swiss Life Sciences Database, such as basic network resources. Small Business Administration, Switzerland, the Swiss Business Association, the Swiss pharmaceutical research companies, the Swiss Chemical Industry Association, the Swiss Chamber of Commerce and other agencies communicate Biology industries are also involved in related activities. 2005 Bioindustry Association (JBA) and the Swiss Biotech Association (SBA) signed a memorandum of understanding to strengthen the two countries in cooperation in the field of biotechnology.

3 research closely with the Swiss biotechnology industry are an important feature of

Ongoing scientific and technological innovation capacity is to maintain the competitiveness of national science and technology a key factor, the Swiss Government is committed to long-term ability to strengthen national scientific and technological innovation, and integration with the private sector, such as the creation of an incubator of innovation framework to encourage private investors to provide funding for innovative enterprises. Excellent ability to continuous innovation in biotechnology in Switzerland in a position of long-term competitiveness. Switzerland, directly involved in the research and development of the national staff of about 50,000 people, R & D investment accounted for 2.6 percent of GDP, one of the public R & D investment accounted for 22.7%. 2004-2006 National R & D in Switzerland for new products, new technology development costs accounted for 44%, 67% invested enterprises, accounting for the federal government and state in 33% (Ernst & Young). Technical papers on the biology of the relative quoted in terms of frequency, Switzerland immunology at the first world, ranking second in the world of molecular biology, pharmacology ranked fifth in the world. Swiss per capita number of scientific papers published the first in the world, of which more than 70% from public universities in science and technology publications. Switzerland, in 2005 the per capita number of patents (EPO) in the world, of which 90% of patent applicants are enterprises, universities accounted for only 0.8%.

2003 CTI Start SystemsX projects, integration of the existing technical and intellectual resources, the promotion of systems biology research. CTI Discovery projects and the fundamental innovation projects are funded high-tech, high-risk but have good prospects for commercial projects. Switzerland Switzerland in 2003 to set up technical conversion Association (SwissTT), there are more than 80 members, in public research institutions and industry partners to create a display of new technology and promote the commercialization of a unique portal. Created in 2004 the Swiss Innovation Promotion (SwissIPA), aims to promote Switzerland and East Asia in the application of international cooperation in the field of scientific research. In addition, the majority of the University of Switzerland have set up technology transfer offices (TTO), the research results through patent applications, deal with intellectual property rights of academic research to assess the commercial potential of science and invention, with potential industrial partners, such as negotiating and signing to promote the technologies and products the transfer of scientific research personnel will assist the industrialization of research results and to cooperate with the outside. Knowledge and technology transfer to encourage and support center (KTT) Swiss innovation system is also an important component of ,2005-2007年CTI to provide 10 million Swiss francs to support the building of the University Center for KTT.

Related analysis market survey Report >>

• Countries in the development of alternatives to plastic bags Investigation and Analysis
• Polysilicon industry market research analysis
• China Alumina Industry Review and Analysis
• Market research analysis of ceramic fiber
• plastic pipe industry, prospects for the development of analysis
• New type of gypsum board market analysis and investigate the prospects for prediction
• Japanese circuit board investigate the development of the market analysis
• Solar power, LED industry growth good
• Top Ten in 2008 predicted that the semiconductor industry
• Voice of Chinese electricity industry trends and market research analysis
• Development Trend of China’s timber industry and market research analysis
• China’s polysilicon industry market research analysis of the future
• The advantages and disadvantages of glass curtain wall
• China’s glass fiber industry market research analysis
• Chinese flexible packaging market research analysis

Contact us,I’m
Online!